Please assess the completion status of the following clinical trial:

Trial Title: Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* seasonal allergic rhinitis with or without allergic conjunctivitis~* sensitization to grass pollen allergens (confirmed with skin prick tests, conjunctival provocation test, specific IgE)~* symptoms of allergic rhinitis with or without conjunctivitis for at least 2 years before the study~Exclusion Criteria:~* sensitization to allergens, that could interfere with grass pollen~* asthma~* cystic fibrosis~* ciliary dysmotility syndrome~* bronchiectasis~* smoking~* tuberculosis~* neoplastic disease~* chronic sinusitis and nasal polyps~* systemic glucocorticosteroids treatment~* treatment with immunotherapy in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): 20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
- Specific subcutaneous immunotherapy (Type: ACTIVE_COMPARATOR): 21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens

Based on this trial design, predict the completion outcome and termination type (if applicable).